Lucid Diagnostics (LUCD) announced that it had received written notification from the Listing Qualifications Department of the Nasdaq Stock Market that the company was eligible for a 180-day extension to regain compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The company now has until June 16, 2025 to meet the requirement.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LUCD:
- Lucid Diagnostics partners for esophageal precancer detection for firefighters
- Lucid announces publication on EsoGuard in peer-reviewed journal Medicina
- Lucid Diagnostics completes convertible debt refinancing
- Lucid Diagnostics’ Strategic Financial Maneuvering and Agreements
- Lucid Diagnostics submits clinical evidence for EsoGuard Esophagea DNA test